Intersect ENT Announces Appointment of New Vice President of Sales
Mark L. Alley to serve as Vice President of Sales
MENLO PARK, Calif.–(BUSINESS WIRE)–Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the appointment of Mark L. Alley as Vice President of Sales, effective May 10, 2021.
Mr. Alley previously served as Chief Commercial Officer at medical device specialist Levita Magnetics Corp. He is a proven leader with over 20 years of commercial and sales success in companies ranging in size from start-ups to Fortune 500 companies in medical devices, capital, and consumables. Importantly, Mark has extensive experience in the Ear, Nose and Throat (ENT) space. He understands Intersect ENT’s broadening technology portfolio and has direct connections to many of the physicians and customers Intersect ENT serves.
“Mark has a reputation for building and developing strong teams that achieve consistent commercial success,” said Thomas A. West, President and Chief Executive Officer of Intersect ENT. “He is passionate and knowledgeable about the ENT market offering the promise of a rapid assimilation into our company. We are excited to have Mark join our team and look forward to his contributing toward our increasing momentum.”
Alley’s previous ENT experience includes serving as Vice President of Sales at Stryker ENT after the company’s acquisition of ear, nose and throat start-up Entellus Medical where Alley also served as Vice President of Sales. In addition, Alley led ENT Sales at Spirox Inc. following a six-year tenure with increasing sales responsibility at sinus balloon pioneer, Acclarent Inc. Alley is a graduate of Butler University with a B.S. in Marketing.
About Intersect ENT
Intersect ENT is a global ear, nose and throat medical technology leader dedicated to transforming patient care. The Company’s steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the Company’s unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care. In October 2020, Intersect ENT acquired Fiagon AG Medical Technologies, a global leader in electromagnetic surgical navigation solutions with an expansive portfolio of ENT product offerings, including the VENSURE sinus balloon, that complement the Company’s PROPEL® and SINUVA® sinus implants and extend its geographic reach.
For additional information on the Company or the products including risks and benefits please visit www.IntersectENT.com. For more information about PROPEL® (mometasone furoate) sinus implants and SINUVA® (mometasone furoate) sinus implant, please visit www.PROPELOPENS.com and www.SINUVA.com.
Intersect ENT®, PROPEL® and SINUVA® are registered trademarks of Intersect ENT, Inc.
Contacts
IR Contact:
Randy Meier, 650-641-2105
Executive Vice-President & CFO
ir@intersectENT.com
Media Contact:
Erich Sandoval, 917-497-2867
Finn Partners for Intersect ENT
IntersectENT@finnpartners.com
